Within the University of Virginia Cancer Center, the Protocol Review Committee, and the Data and Safety Monitoring Committee provide the infrastructure for scientific oversight and monitoring of institutional cancer related clinical trials. The Data and Safety Monitoring Committee provides oversight of the conduct of all ongoing UVa investigator-initiated clinical trials that have been approved by the Protocol Review Committee. For those studies the committee is charged with monitoring, their duties include review of study specific data and safety monitoring plans; adverse events including frequency and patterns of adverse events; protocol violations; audit findings; accrual rates; and adherence to protocol specific escalation or deescalation guidelines, or early stopping guidelines. The protocol specific risk.level assigned by the Protocol Review Committee determines the degree of monitoring.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-18
Application #
7726766
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-02-01
Budget End
2009-01-31
Support Year
18
Fiscal Year
2008
Total Cost
$43,653
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255

Showing the most recent 10 out of 539 publications